BRAF and neoplasm: Plasma circulating tumor DNA (ctDNA) analysis before treatment may allow selection of patients who could benefit, as median OS and PFS were longer in patients with RAS/BRAF WT ctDNA (17.3 vs. 10.4 months, p = 0.02, and 4.1 vs. 3.0 months, p = 0.004, respectively).